Elevated Osteoprotegerin Predicts Declining Renal Function in Elderly Women: A 10-Year Prospective Cohort Study

American Journal of Nephrology

Volumn 39, Issue 1, 2014, Pages 66-74

  Lewis, Joshua R ^a,b,c   Lim, Wai H ^a,c   Zhu, Kun ^a,b   Wong, Germaine ^e   Dhaliwal, Satvinder S ^d   Lim, Ee M ^b,c   Ueland, Thor ^f   Bollerslev, Jens ^f   Prince, Richard L ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b Department of Endocrinology and Diabetes ^*  (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d CURTIN UNIVERSITY   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

CKD EPI; Creatinine and cystatin C; Estimated glomerular filtration rate; Osteoprotegerin; Renal decline

Indexed keywords

CALCIUM; CREATININE; CYSTATIN C; OSTEOPROTEGERIN; PLACEBO;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUPPLEMENTATION;

AGED; BIOLOGICAL MARKERS; CREATININE; CYSTATIN C; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LONGITUDINAL STUDIES; MULTIVARIATE ANALYSIS; OSTEOPROTEGERIN; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 84896732676     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000357787     Document Type: Article

References (41)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
2. Lewis JR, Lim W, Dhaliwal SS, Zhu K, Lim EM, Thompson PL, Prince RL: Estimated glomerular filtration rate as an independent predictor of atherosclerotic vascular disease in older women. BMC Nephrol 2012; 13: 58.
3. Lim WH, Lewis JR, Wong G, Dogra GK, Zhu K, Lim EM, Dhaliwal SS, Prince RL: Five-year decline in estimated glomerular filtration rate associated with a higher risk of renal disease and atherosclerotic vascular disease clinical events in elderly women. QJM 2013; 106: 443-450.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-319.
5. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
6. Chino T, Draves KE, Clark EA: Regulation of dendritic cell survival and cytokine production by osteoprotegerin. J Leukoc Biol 2009; 86: 933-940.
7. Shin JY, Shin YG, Chung CH: Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care 2006; 29: 1664-1666.
8. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y: Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002; 106: 1192-1194.
9. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R: The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 2006; 47: 1850-1857.
10. Schoppet M, Preissner KT, Hofbauer LC: Rank ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 2002; 22: 549-553.
11. Altinova AE, Toruner F, Akturk M, Bukan N, Yetkin I, Cakir N, Arslan M: Relationship between serum osteoprotegerin, glycemic control, renal function and markers of atherosclerosis in type 2 diabetes. Scand J Clin Lab Invest 2011; 71: 340-343.
12. Scialla JJ, Leonard MB, Townsend RR, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, Hanish A, Raj D, Rosas SE, Seliger SL, Weir MR, Parekh RS: Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2612-2619.
13. Prince RL, Devine A, Dhaliwal SS, Dick IM: Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006; 166: 869-875.
14. Ueland T, Bollerslev J, Wilson SG, Dick IM, Islam FM, Mullin BH, Devine A, Prince RL: No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. Bone 2007; 40: 175-181.
15. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, Aukrust P: Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess - possible role in bone homeostasis. Eur J Endocrinol 2001; 145: 685-690.
16. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YL, Coresh J, Levey AS: Estimating glomerular filtration rate from serum creatinine and cystatin c. N Engl J Med 2012; 367: 20-29.
17. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, Newman AB, Sarnak MJ: Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008; 168: 2212-2218.
18. Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, Rifkin D, Sarnak MJ: Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol 2009; 20: 2625-2630.
19. Robinson-Cohen C, Katz R, Mozaffarian D, Dalrymple LS, de Boer I, Sarnak M, Shlipak M, Siscovick D, Kestenbaum B: Physical activity and rapid decline in kidney function among older adults. Arch Intern Med 2009; 169: 2116-2123.
20. World Health Organization: Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death: Based on the Recommendations of the 9th Revision Conference, 1975, and adopted by the 29th World Health Assembly, ed 1975 rev. Geneva, WHO, 1977.
21. World Health Organization: ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th rev, ed 2. Geneva, WHO, 2004.
22. Holman CD, Bass AJ, Rosman DL, Smith MB, Semmens JB, Glasson EJ, Brook EL, Trutwein B, Rouse IL, Watson CR, de Klerk NH, Stanley FJ: A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. Aust Health Rev 2008; 32: 766-777.
23. Ueland T, Wilson SG, Amirul Islam FM, Mullin B, Devine A, Bollerslev J, Zhu K, Prince RL: A cohort study of the effects of serum OPG and OPG gene polymorphisms on cardiovascular mortality in elderly women. Clin Endocrinol (Oxf) 2009; 71: 828-833.
24. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
25. Lieb W, Gona P, Larson MG, Massaro JM, Lipinska I, Keaney JF Jr, Rong J, Corey D, Hoffmann U, Fox CS, Vasan RS, Benjamin EJ, O'Donnell CJ, Kathiresan S: Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler Thromb Vasc Biol 2010; 30: 1849-1854.
26. Vik A, Mathiesen EB, Brox J, Wilsgaard T, Njolstad I, Jorgensen L, Hansen JB: Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost 2011; 9: 638-644.
27. Ueland T, Aukrust P, Dahl CP, Husebye T, Solberg OG, Tonnessen T, Aakhus S, Gullestad L: Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis. J Intern Med 2011; 270: 452-460.
28. Jorsal A, Tarnow L, Flyvbjerg A, Parving HH, Rossing P, Rasmussen LM: Plasma osteoprotegerin levels predict cardiovascular and allcause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia 2008; 51: 2100-2107.
29. Matsubara K, Stenvinkel P, Qureshi AR, Carrero JJ, Axelsson J, Heimburger O, Barany P, Alvestrand A, Lindholm B, Suliman ME: Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 2009; 22: 774-782.
30. Mesquita M, Demulder A, Wolff F, Melot C, Damry N, Dratwa M, Bergmann P: Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease. Transplant Proc 2010; 42: 3444-3449.
31. Nishiura R, Fujimoto S, Sato Y, Yamada K, Hisanaga S, Hara S, Nakao H, Kitamura K: Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol 2009; 29: 257-263.
32. Corallini F, Gonelli A, D'Aurizio F, di Iasio MG, Vaccarezza M: Mesenchymal stem cellsderived vascular smooth muscle cells release abundant levels of osteoprotegerin. Eur J Histochem 2009; 53: 19-24.
33. Olesen P, Ledet T, Rasmussen LM: Arterial osteoprotegerin: Increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-V. Diabetologia 2005; 48: 561-568.
34. Bargnoux AS, Dupuy AM, Garrigue V, Jaussent I, Gahide G, Badiou S, Szwarc I, Deleuze S, Vernhet H, Cristol JP, Mourad G: Evolution of coronary artery calcifications following kidney transplantation: relationship with osteoprotegerin levels. Am J Transplant 2009; 9: 2571-2579.
35. Kazama JJ, Kato H, Sato T, Shigematsu T, Fukagawa M, Iwasaki Y, Gejyo F: Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 2002; 17: 1860-1861.
36. Sato T, Tominaga Y, Iwasaki Y, Kazama JJ, Shigematsu T, Inagaki H, Watanabe I, Katayama A, Haba T, Uchida K, Fukagawa M: Osteoprotegerin levels before and after renal transplantation. Am J Kidney Dis 2001; 38:S175-S177.
37. Khosla S, Arrighi HM, Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Dunstan C, Riggs BL: Correlates of osteoprotegerin levels in women and men. Osteoporos Int 2002; 13: 394-399.
38. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman- Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005; 352: 2049-2060.
39. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246.
40. Emberson JR, Haynes R, Dasgupta T, Mafham M, Landray MJ, Baigent C, Clarke R: Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men. J Intern Med 2010; 268: 145-154.
41. Menon V, Shlipak MG, Wang X, Coresh J, Greene T, Stevens L, Kusek JW, Beck GJ, Collins AJ, Levey AS, Sarnak MJ: Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann Intern Med 2007; 147: 19-27.